Abstracts tagged "metabolism and mitochondria"

Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Félix Renaudin ¹, Laure Campillo-Gimenez ², Florence Castelli ³, François Fenaille ³, Aurélie Prignon ⁴, Christele Combes ⁵, Martine Cohen-Solal ¹, Frédéric Lioté ⁶ and Hang Korng Ea¹, ¹Université Paris, INSERM UMR1132 BIOSCAR, Paris, France, ²Université Paris, INSERM UMR1132 BIOSCAR, San Diego, ³CEA Paris-Saclay, Laboratoire d’Etudes du Métabolisme des Médicaments, Saclay, France, ⁴UMS28 Phénotypage du petit animal, Laboratoire d'Imagerie Moléculaire Positonique (LIMP), Sorbonne Univerity, Paris, France, ⁵CIRIMAT, Université de Toulouse, INPT,UPS,CNRS,ENSIACET, Toulouse, France, ⁶Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France
Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…
Abstract Number: 284 • 2017 ACR/ARHP Annual Meeting
Metabolic Activity Sustains Macrophage Cytokine Production in Rheumatoid Arthritis and Coronary Artery Disease
Cornelia M. Weyand¹, Markus Zeisbrich¹, Lukas Brosig², Barbara Wallis¹, Niall Roche³, Janice Lin¹ and Jorg Goronzy⁴, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University, Stanfod, CA, ³The Arthritis Center, Pleasanton, CA, ⁴Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Accelerated atherosclerosis has become increasingly recognized as a complication of chronic inflammatory disease, such as in patients with rheumatoid arthritis (RA). RA patients have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].